Literature DB >> 19951967

Enhanced sensitivity of flow cytometry for routine assessment of minimal residual disease.

Esther Domingo, Cristina Moreno, Alfonso Sánchez-Ibarrola, Carlos Panizo, José Antonio Páramo, Juana Merino.   

Abstract

Mesh:

Year:  2009        PMID: 19951967      PMCID: PMC2857207          DOI: 10.3324/haematol.2009.018911

Source DB:  PubMed          Journal:  Haematologica        ISSN: 0390-6078            Impact factor:   9.941


× No keyword cloud information.
  11 in total

1.  A single-tube six-colour flow cytometry screening assay for the detection of minimal residual disease in myeloma.

Authors:  R M de Tute; A S Jack; J A Child; G J Morgan; R G Owen; A C Rawstron
Journal:  Leukemia       Date:  2007-07-26       Impact factor: 11.528

2.  Multiparameter flow cytometric remission is the most relevant prognostic factor for multiple myeloma patients who undergo autologous stem cell transplantation.

Authors:  Bruno Paiva; Maria-Belén Vidriales; Jorge Cerveró; Gema Mateo; Jose J Pérez; Maria A Montalbán; Anna Sureda; Laura Montejano; Norma C Gutiérrez; Alfonso García de Coca; Natalia de Las Heras; Maria V Mateos; Maria C López-Berges; Raimundo García-Boyero; Josefina Galende; Jose Hernández; Luis Palomera; Dolores Carrera; Rafael Martínez; Javier de la Rubia; Alejandro Martín; Joan Bladé; Juan J Lahuerta; Alberto Orfao; Jesús F San Miguel
Journal:  Blood       Date:  2008-07-31       Impact factor: 22.113

3.  Methodological approach to minimal residual disease detection by flow cytometry in adult B-lineage acute lymphoblastic leukemia.

Authors:  Mauro Krampera; Omar Perbellini; Carlo Vincenzi; Francesca Zampieri; Annalisa Pasini; Maria Teresa Scupoli; Anna Guarini; Maria Stefania De Propris; Elaine Coustan-Smith; Dario Campana; Robin Foà; Giovanni Pizzolo
Journal:  Haematologica       Date:  2006-08       Impact factor: 9.941

4.  Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia and its relationship to other prognostic factors: a Children's Oncology Group study.

Authors:  Michael J Borowitz; Meenakshi Devidas; Stephen P Hunger; W Paul Bowman; Andrew J Carroll; William L Carroll; Stephen Linda; Paul L Martin; D Jeanette Pullen; David Viswanatha; Cheryl L Willman; Naomi Winick; Bruce M Camitta
Journal:  Blood       Date:  2008-04-03       Impact factor: 22.113

5.  Establishment and validation of a standard protocol for the detection of minimal residual disease in B lineage childhood acute lymphoblastic leukemia by flow cytometry in a multi-center setting.

Authors:  Julie Irving; Jenny Jesson; Paul Virgo; Marian Case; Lynne Minto; Lisa Eyre; Nigel Noel; Ulrika Johansson; Marion Macey; Linda Knotts; Margaret Helliwell; Paul Davies; Liam Whitby; David Barnett; Jeremy Hancock; Nick Goulden; Sarah Lawson
Journal:  Haematologica       Date:  2009-04-18       Impact factor: 9.941

Review 6.  Minimal residual disease in acute lymphoblastic leukemia.

Authors:  Dario Campana
Journal:  Semin Hematol       Date:  2009-01       Impact factor: 3.851

7.  Standardization of flow cytometric minimal residual disease evaluation in acute lymphoblastic leukemia: Multicentric assessment is feasible.

Authors:  Michael Norbert Dworzak; Giuseppe Gaipa; Richard Ratei; Marinella Veltroni; Angela Schumich; Oscar Maglia; Leonid Karawajew; Allessandra Benetello; Ulrike Pötschger; Zvenyslava Husak; Helmut Gadner; Andrea Biondi; Wolf-Dieter Ludwig; Giuseppe Basso
Journal:  Cytometry B Clin Cytom       Date:  2008-11       Impact factor: 3.058

8.  International standardized approach for flow cytometric residual disease monitoring in chronic lymphocytic leukaemia.

Authors:  A C Rawstron; N Villamor; M Ritgen; S Böttcher; P Ghia; J L Zehnder; G Lozanski; D Colomer; C Moreno; M Geuna; P A S Evans; Y Natkunam; S E Coutre; E D Avery; L Z Rassenti; T J Kipps; F Caligaris-Cappio; M Kneba; J C Byrd; M J Hallek; E Montserrat; P Hillmen
Journal:  Leukemia       Date:  2007-03-15       Impact factor: 11.528

Review 9.  Flow cytometric immunophenotyping for hematologic neoplasms.

Authors:  Fiona E Craig; Kenneth A Foon
Journal:  Blood       Date:  2008-01-15       Impact factor: 22.113

10.  Report of the European Myeloma Network on multiparametric flow cytometry in multiple myeloma and related disorders.

Authors:  Andy C Rawstron; Alberto Orfao; Meral Beksac; Ludmila Bezdickova; Rik A Brooimans; Horia Bumbea; Klara Dalva; Gwenny Fuhler; Jan Gratama; Dirk Hose; Lucie Kovarova; Michael Lioznov; Gema Mateo; Ricardo Morilla; Anne K Mylin; Paola Omedé; Catherine Pellat-Deceunynck; Martin Perez Andres; Maria Petrucci; Marina Ruggeri; Grzegorz Rymkiewicz; Alexander Schmitz; Martin Schreder; Carine Seynaeve; Martin Spacek; Ruth M de Tute; Els Van Valckenborgh; Nicky Weston-Bell; Roger G Owen; Jesús F San Miguel; Pieter Sonneveld; Hans E Johnsen
Journal:  Haematologica       Date:  2008-02-11       Impact factor: 9.941

View more
  2 in total

1.  Differential effects of lenalidomide during plasma cell differentiation.

Authors:  Michel Jourdan; Maïlys Cren; Peter Schafer; Nicolas Robert; Christophe Duperray; Laure Vincent; Patrice Ceballos; Guillaume Cartron; Jean-François Rossi; Jérôme Moreaux; Rajesh Chopra; Bernard Klein
Journal:  Oncotarget       Date:  2016-05-10

2.  Residual malignant and normal plasma cells shortly after high dose melphalan and stem cell transplantation. Highlight of a putative therapeutic window in Multiple Myeloma?

Authors:  Anouk Caraux; Laure Vincent; Salahedine Bouhya; Philippe Quittet; Jérôme Moreaux; Guilhem Requirand; Jean-Luc Veyrune; Gaëlle Olivier; Guillaume Cartron; Jean-François Rossi; Bernard Klein
Journal:  Oncotarget       Date:  2012-11
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.